Come see my latest article on psychedelics in inBusiness Magazine:
While widely used in various forms for thousands for years, psychedelic substances that have been admonished in recent decades are receiving renewed interest for their medicinal properties. For instance, phase 3 studies are underway for MDMA-assisted psychotherapy for PTSD, setting the stage for a probable return to prescription status. Following close behind, psilocybin mushroom medicines are on fast track by the Food and Drug Administration for approval for treatment of anxiety and depression. It is anticipated that within two years, the FDA will approve MDMA (methylenedioxy-methamphetamine, commonly known as Ecstasy) and psilocybin therapies….